Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses In Excess Of $100,000 Investing In Dynavax Technologies Corporation To Contact The Firm
NEW YORK, June 21, 2013 /PRNewswire/ -- Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential securities fraud at Dynavax Technologies Corporation ("Dynavax" or the "Company") (NASDAQ: DVAX).
The investigation focuses on whether Dynavax made materially false and misleading statements regarding the viability of HEPLISAV, the Company's lead product candidate. Specifically, the investigation focuses on whether Dynavax failed to disclose: (i) that the clinical trial for HEPLISAV was flawed in that it was not representative of the United States population and did not provide information regarding concurrent use of HEPLISAV with other vaccines; and (ii) the Company did not provide the Food and Drug Administration ("FDA") with adequate information regarding HEPLISAV manufacturing processes and controls.
On June 10, 2013, Dynavax issued a press release announcing that the FDA would require additional safety trials prior to granting approval of HEPLISAV. Following this news, Dynavax's stock price dropped $1.07 or 43%.
Request more information now by clicking here: www.faruqilaw.com/DVAX. There is no cost or obligation to you.
If you invested in Dynavax stock or options between April 26, 2012 and June 10, 2013 and would like to discuss your legal rights, visit www.faruqilaw.com/DVAX. You can also contact us by calling Richard Gonnello or Francis McConville toll free at 877-247-4292 or at 212-983-9330 or by sending an e-mail to firstname.lastname@example.org or email@example.com. Faruqi & Faruqi, LLP also encourages anyone with information regarding Dynavax's conduct to contact the firm, including whistleblowers, former employees, shareholders and others.
Attorney Advertising. The law firm responsible for this advertisement is Faruqi & Faruqi, LLP (www.faruqilaw.com). Prior results do not guarantee or predict a similar outcome with respect to any future matter. We welcome the opportunity to discuss your particular case. All communications will be treated in a confidential manner.
FARUQI & FARUQI, LLP
369 Lexington Avenue, 10th Floor
New York, NY 10017
Attn: Richard Gonnello, Esq.
Francis McConville, Esq.
Telephone: (877) 247-4292 or (212) 983-9330
SOURCE Faruqi & Faruqi, LLP
More by this Source
Faruqi & Faruqi, LLP Files Class Action Lawsuit Against ARIAD Pharmaceuticals, Inc. (ARIA)
Dec 06, 2013, 20:00 ET
Faruqi & Faruqi, LLP is Investigating Gas Natural Inc. on Behalf of its Shareholders - EGAS
Dec 06, 2013, 10:56 ET
Browse our custom packages or build your own to meet your unique communications needs.
Learn about PR Newswire services
Request more information about PR Newswire products and services or call us at (888) 776-0942.